Alnylam Pharmaceuticals Inc (ALNY)

[surf1944]

8:02AM Alnylam initiates Phase II clinical trial of ALN-TTR02 (ALNY) 11.04 : Co announced that it has completed enrollment in its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). Alnylam also announced today that it has initiated a Phase II trial with ALN-TTR02 aimed at evaluating clinical activity, safety, and tolerability of multiple once-monthly doses of ALN-TTR02 in ATTR patients. Specifically, the study will evaluate the clinical activity of ALN-TTR02 based on measurement of serum levels of TTR, the disease-causing protein in patients with ATTR. ALN-TTR02 utilizes the company's proprietary second-generation lipid nanoparticle (LNP) delivery technology using the "MC3" lipid. The company expects to present data from the Phase I trial early in the third quarter of 2012.